MX382044B - Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés. - Google Patents

Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés.

Info

Publication number
MX382044B
MX382044B MX2017010654A MX2017010654A MX382044B MX 382044 B MX382044 B MX 382044B MX 2017010654 A MX2017010654 A MX 2017010654A MX 2017010654 A MX2017010654 A MX 2017010654A MX 382044 B MX382044 B MX 382044B
Authority
MX
Mexico
Prior art keywords
depressive
oxabicycloheptenes
oxabicycloheptanes
treatment
stress disorders
Prior art date
Application number
MX2017010654A
Other languages
English (en)
Other versions
MX2017010654A (es
Inventor
John S Kovach
Manuel Mameli
Salvatore Lecca
Original Assignee
Lixte Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lixte Biotechnology Inc filed Critical Lixte Biotechnology Inc
Publication of MX2017010654A publication Critical patent/MX2017010654A/es
Publication of MX382044B publication Critical patent/MX382044B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/32—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by aldehydo- or ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un método para el tratamiento de trastorno depresivo o de estrés en un sujeto afectado con el mismo, que comprenden administrar al sujeto una cantidad eficaz de un compuesto que tiene la estructura: (I) (ver Fórmula).
MX2017010654A 2015-02-19 2016-02-19 Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés. MX382044B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562118246P 2015-02-19 2015-02-19
US201662279265P 2016-01-15 2016-01-15
PCT/US2016/018679 WO2016134257A1 (en) 2015-02-19 2016-02-19 Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders

Publications (2)

Publication Number Publication Date
MX2017010654A MX2017010654A (es) 2019-01-30
MX382044B true MX382044B (es) 2025-03-13

Family

ID=56689326

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017010654A MX382044B (es) 2015-02-19 2016-02-19 Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés.

Country Status (6)

Country Link
US (2) US9833450B2 (es)
EP (1) EP3258930B1 (es)
AU (1) AU2016219853B2 (es)
CA (1) CA2977256C (es)
MX (1) MX382044B (es)
WO (1) WO2016134257A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2877167A1 (en) 2012-06-29 2014-01-03 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes
AU2014251087B2 (en) 2013-04-09 2019-05-02 Lixte Biotechnology, Inc. Formulations of oxabicycloheptanes and oxabicycloheptenes
US10071094B2 (en) 2014-07-24 2018-09-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes
US9833450B2 (en) 2015-02-19 2017-12-05 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders
CN107708686B (zh) 2015-05-15 2021-02-19 莱克斯特生物技术公司 氧杂二环庚烷前药
NZ754522A (en) 2016-12-08 2025-11-28 Lixte Biotechnology Inc Oxabicycloheptanes for modulation of immune response

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361436A (en) * 1977-09-16 1982-11-30 Gaf Corporation Composition for plant growth regulation
US4614825A (en) * 1982-05-17 1986-09-30 E. R. Squibb & Sons, Inc. 7-oxabicycloheptane and 7-oxabicycloheptene compounds
JPH0723367B2 (ja) * 1986-02-27 1995-03-15 サントリー株式会社 オキサビシクロヘプタン誘導体
US4931460A (en) * 1987-09-17 1990-06-05 E. R. Squibb & Sons, Inc. Post-ischemic myocardial dysfunction using thromboxane A2 antagonists
US4900723A (en) * 1988-04-29 1990-02-13 E. R. Squibb & Sons, Inc. Method of preventing or reducing venous thrombosis using a thromboxane A2 receptor antagonist in conjunction with heparin and combination
US6440726B1 (en) * 1998-12-24 2002-08-27 Florence Medical, Ltd. Expression vectors comprising multiple shear stress responsive elements (SSRE) and methods of use for treating disorders related to vasculogenesis and/or angiogenesis in a shear stress environment
JP2004538323A (ja) * 2001-08-10 2004-12-24 ザ ロックフェラー ユニバーシティー Ｄａｒｐｐ−３２リン酸化のモジュレーションのための組成物及び方法
US7022410B2 (en) * 2003-12-16 2006-04-04 General Electric Company Combinations of resin compositions and methods of use thereof
US20050049334A1 (en) * 2003-09-03 2005-03-03 Slawomir Rubinsztain Solvent-modified resin system containing filler that has high Tg, transparency and good reliability in wafer level underfill applications
US20050266263A1 (en) * 2002-11-22 2005-12-01 General Electric Company Refractory solid, adhesive composition, and device, and associated method
US20050170188A1 (en) * 2003-09-03 2005-08-04 General Electric Company Resin compositions and methods of use thereof
US20060147719A1 (en) * 2002-11-22 2006-07-06 Slawomir Rubinsztajn Curable composition, underfill, and method
WO2007092414A2 (en) 2006-02-06 2007-08-16 Lixte Biotechnology Holdings, Inc. Use of phosphatases to treat tumors overexpressing n-cor
US7998957B2 (en) 2007-02-06 2011-08-16 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use
WO2008100423A1 (en) * 2007-02-09 2008-08-21 Sirtris Pharmaceuticals, Inc. Gut microsomal triglyceride transport protein inhibitors
CA2718472A1 (en) 2007-08-03 2009-02-12 Lixte Biotechnology, Inc. Use of phosphatases to treat neuroblastomas and medulloblastomas
ES2628748T3 (es) 2007-10-01 2017-08-03 Lixte Biotechnology, Inc. Inhibidores de la HDAC
WO2010147612A1 (en) * 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
AU2009277179A1 (en) 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
WO2010014220A1 (en) 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
US8227473B2 (en) * 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
US8101600B2 (en) * 2008-12-23 2012-01-24 Brookhaven Science Associates, Llc Method of treating depression
US20120135522A1 (en) * 2009-06-18 2012-05-31 Kovach John S Methods of modulating cell regulation by inhibiting p53
US9040129B2 (en) * 2010-04-26 2015-05-26 Fujifilm Corporation Protective film of polarizer, polarizer and method for producing it, and liquid crystal display device
BR112013000744A2 (pt) * 2010-07-14 2020-07-14 Cumberland Emerging Technologies, Inc uso de um antagonista de receptor de tromboxana a2 para prevenção ou tratamento de síndrome hepatorrenal,encefalopatia hepática,e doenças associadas
EP2714924B1 (en) * 2011-05-24 2018-03-21 Lixte Biotechnology, Inc. HDAC Inhibitors for use in the treatment of Gaucher's disease, von Hippel-Lindau disease, phaeochromocytoma and paragangliomas.
KR101614627B1 (ko) * 2011-08-31 2016-04-21 아사히 가세이 이-매터리얼즈 가부시키가이샤 감광성 알칼리 가용 실리콘 수지 조성물
CN104619710B (zh) * 2012-06-29 2017-09-22 里克思特生物技术有限公司 用于治疗再灌注损伤的氧杂二环庚烷和氧杂二环庚烯
CA2877167A1 (en) * 2012-06-29 2014-01-03 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes
EP2964026A4 (en) 2013-03-05 2016-08-17 Lixte Biotechnology Inc HDAC INHIBITORS FOR THE TREATMENT OF TRAUMATIC BRAIN INJURY
US10568328B2 (en) * 2013-03-15 2020-02-25 Monsanto Technology Llc Methods and compositions for weed control
EP2968279A4 (en) 2013-03-15 2016-09-28 Lixte Biotechnology Inc SANGUINARIN ANALOG PPC2 HEMMER FOR CANCER TREATMENT
AU2014251087B2 (en) * 2013-04-09 2019-05-02 Lixte Biotechnology, Inc. Formulations of oxabicycloheptanes and oxabicycloheptenes
WO2015073802A1 (en) 2013-11-15 2015-05-21 Lixte Biotechnology, Inc. Protein phosphatase inhibitors that cross the blood brain barrier
AU2015258805B2 (en) * 2014-05-16 2018-05-10 Cumberland Pharmaceuticals, Inc. Compositions and methods of treating cardiac fibrosis with ifetroban
US20170136008A1 (en) 2014-06-20 2017-05-18 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of ovarian cancer
US10071094B2 (en) 2014-07-24 2018-09-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes
CA2960989A1 (en) 2014-09-12 2016-03-17 Lixte Biotechnology, Inc. Human dosing of phosphatase inhibitor
WO2016061193A1 (en) 2014-10-15 2016-04-21 Lixte Biotechnology, Inc. Process of synthesizing 3-(4-methylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1] heptane-2-carboxylic acid
US9833450B2 (en) 2015-02-19 2017-12-05 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders
CN107708686B (zh) 2015-05-15 2021-02-19 莱克斯特生物技术公司 氧杂二环庚烷前药

Also Published As

Publication number Publication date
CA2977256A1 (en) 2016-08-25
US10413541B2 (en) 2019-09-17
EP3258930B1 (en) 2020-12-09
CA2977256C (en) 2023-08-08
WO2016134257A8 (en) 2017-09-14
EP3258930A4 (en) 2018-10-17
US9833450B2 (en) 2017-12-05
US20160303115A1 (en) 2016-10-20
MX2017010654A (es) 2019-01-30
WO2016134257A1 (en) 2016-08-25
US20180256565A1 (en) 2018-09-13
AU2016219853A1 (en) 2017-09-14
EP3258930A1 (en) 2017-12-27
AU2016219853B2 (en) 2019-05-16

Similar Documents

Publication Publication Date Title
MX2018004947A (es) Metodos para el tratamiento de sindrome de angelman y de los trastornos relacionados.
MA40437A (fr) Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux
PH12015502075B1 (en) Treatment of cataplexy
MX370506B (es) Método para tratar trastorno de estrés post-traumático.
MX2019002190A (es) Uso de pridopidina para tratar distonías.
MX382044B (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés.
BR112019005040A2 (pt) aplicação de pridopidina para tratamento de síndrome de rett
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
MY203831A (en) Treatment and diagnosis of inflammatory disorders
TW201613610A (en) Use of ginsenoside M1 for treating lupus nephritis
MX2019004804A (es) Tratamiento para el prurigo nodula.
EA201690446A1 (ru) Лечение множественной миеломы
EA201690445A1 (ru) Лечение рака
MX2021014120A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
NZ724799A (en) Compositions and methods for the treatment or prevention of neurodegenerative disorders
PH12016501658A1 (en) Sialylated glycoprotein compositions and uses thereof
IL258316A (en) A combination of trazodone and gabapentin for the treatment of pain
MX2016010967A (es) Nuevas composiciones para tratar lesiones neuronales mecanicas.
MX2015009907A (es) Metodo para tratar y curar leishmaniosis usando fexinidazol.
UA103888U (uk) Розчин фенолу для ін'єкцій для лікування хронічного больового синдрому
MX2018003040A (es) Metodos para el tratamiento de formas recurrentes de esclerosis multiple.
MA39718A (fr) Compositions et méthodes d'utilisation de celles-ci
UA97357U (en) Method for laser therapy in the treatment of patients with exogenous depressive disorder with suicidal behavior
UA84216U (ru) Способ лечения неврита зрительного нерва